Mohyuddin Ghulam Rehman, Clark Ashley Elizabeth, Roller John, Shune Leyla, Lin Tara, Dunavin Neil, Dias Ajoy, Ganguly Siddhartha, Abhyankar Sunil, McGuirk Joseph, Singh Anurag
Division of Hematologic Malignancies and Cellular Therapeutic (HMCT), University of Kansas Medical Center, Kansas City, KS, USA.
Acta Haematol. 2018;139(1):52-57. doi: 10.1159/000484549. Epub 2018 Jan 17.
Surveillance scans performed after autologous stem cell transplant (auto-HCT) for patients with Hodgkin disease (HD) have no proven survival benefit.
We studied survival differences among patients with HD after auto-HCT whose recurrences were detected on clinical history and exam, versus those detected on routine surveillance scan.
Among the 98 patients with HD that underwent auto-HCT from 2000 to 2014 at our institution, 30 relapsed, of which 21 were detected radiologically and 9 clinically. There were no statistically significant differences in patient characteristics between the 2 groups. The median time to progression was 118 days for the clinical cohort and 284 days for the radiological cohort (p = 0.05). Median overall survival (OS) was 728 days for the clinical cohort, and was not reached for the radiological cohort (p = 0.02).
In our review, most patients with HD after auto-HCT were diagnosed radiologically. Patients whose relapse was diagnosed clinically were likely to be detected earlier and have a shorter OS. Patients with aggressive disease may be detected when clinically relevant, regardless of scanning. Routine scanning may not be necessary in the majority of patients with HD following auto-HCT.
对霍奇金淋巴瘤(HD)患者进行自体干细胞移植(auto-HCT)后的监测扫描并未显示出对生存有明确的益处。
我们研究了auto-HCT后HD患者中,通过临床病史和检查发现复发的患者与通过常规监测扫描发现复发的患者之间的生存差异。
2000年至2014年在我们机构接受auto-HCT的98例HD患者中,30例复发,其中21例通过影像学检测到,9例通过临床检测到。两组患者的特征在统计学上无显著差异。临床队列的中位进展时间为118天,影像学队列的中位进展时间为284天(p = 0.05)。临床队列的中位总生存期(OS)为728天,影像学队列未达到(p = 0.02)。
在我们的综述中,大多数auto-HCT后的HD患者是通过影像学诊断的。临床诊断复发的患者可能更早被发现且总生存期较短。侵袭性疾病患者在出现临床相关症状时可能会被检测到,无论是否进行扫描。对于大多数auto-HCT后的HD患者,常规扫描可能没有必要。